Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Scenarios and speculation

<< Previous

Bullboard Posts

Next >>

Comment by Buckhenryon Feb 04, 2023 10:17pm

173 Views

Post# 35267304

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Scenarios and speculation

im sorry you seem so bitter and have to attack me instead of dealing with the issue at hand. in still waiting fir the soothsaying folks on here that seem to know it all to tell us when the date is.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec